Inhaled corticosteroids or long-acting β-agonists alone or in fixed-dose combinations in asthma treatment: A systematic review of fluticasone/budesonide and formoterol/salmeterol

Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study

“…[25][26][27][28] A recent study of the effects of combination budesonide/formoterol maintenance and reliever therapy in Maori patients with asthma reported reductions in exacerbations and days of high therapy use compared with baseline, which is in accordance with the results presented here. 29 The results of the subgroup analysis indicated that the patients who received previous treatment with salmeterol/fluticasone propionate (either alone or in combination) improved in a similar manner to patients in the Chinese population as a whole.…”

Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA‐based therapeutics for asthma

“…STAT6 expression in lung epithelial cells is exclusively required for IL-13-mediated pathology [7], consistent with the increasing recognition that epithelial cells play a fundamental role in asthma pathogenesis [8, 9]. Against this backdrop, and given the mainstay of asthma therapy continues to rely on the use of inhaled steroids [10], which can have undesired side effects [11], we have developed a more refined therapeutic approach that harnesses the endogenous RNA-interference mechanism to specifically suppress STAT6 expression in epithelial cells using small interfering RNA (siRNA) [12, 13]. However, limitations associated with animal models of allergic asthma [14, 15], a paucity of relevant biomarkers [16, 17] and with particular regard to siRNA-based treatment—the status of target gene expression within the respiratory epithelium of asthma sufferers—mean that the drug-development pathway for new asthma therapeutics can be particularly problematic.…”

Long-Term Safety and Efficacy of Fluticasone/Formoterol Combination Therapy in Asthma

“…48 Moreover, comparison studies suggest no significant differences in AE profile between the different ICS/LABA combinations 43,44,49,50 or between ICS/LABA combinations and ICS therapy alone. 51,52 In the current study, nasal or oropharyngeal AEs made up a notable proportion of the AEs.…”